Advertisement

Apolipoproteins as “Drugs”: Current Status

  • Cesare R. Sirtori
Part of the NATO ASI Series book series (volume 73)

Abstract

Apolipoproteins are attractive molecules for a potential use in therapeutics. They are generally quite stable, capable of binding at the same time lipids and other chemicals, water soluble and in some cases presenting with a dominant positive or negative charge. In addition, some apolipoproteins can interact with cell receptors, either regulating cholesterol biosynthesis, or possibly cholesterol removal.

Keywords

Amphipathic Helix WHHL Rabbit Lipid Binding Property Inhibit Membrane Fusion Mammalian Peripheral Nerve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akerlöf E, Fredricsson B, Gustafson O, Lunell N-O, Nylund L, Rosenborg L, Pousette A (1987) Serum factors stimulate the motility of human spermatozoa. Int J Androl 10: 124–130CrossRefGoogle Scholar
  2. Akerlöf E, Jörnvall H, Slone H, Pousette A (1991) Identification of apolipoprotein Al and immunoglobulin as components of a serum complex that mediates activation of human sperm motility. Biochemistry 30: 8996–8990CrossRefGoogle Scholar
  3. Aoyama T, Yui Y, Morishita H, Kawai C (1990) Prostaglandin 12 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 81: 1784–1791PubMedCrossRefGoogle Scholar
  4. Badimon JJ, Badimon L, Galvez A, Dische A, Fuster V (1989) High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 60: 455–461PubMedGoogle Scholar
  5. Dadimon JJ, Badimon L, Fuster V (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in rabbits. J Clin Invest 85: 1234–1241CrossRefGoogle Scholar
  6. Boyles JK, Notterpek LM, Anderson LJ (1990) Accumulation of apolipoprotein in the regenerating and remyelinating mammalian peripheral nerve. J Biol Chem 265: 17805–17815PubMedGoogle Scholar
  7. Chisari FV, Curtiss LK, Jensen FC (1981) Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lympocytes by Epstein-Barr virus. J Clin Invest 68: 329–336PubMedCrossRefGoogle Scholar
  8. Curtiss LK, Edgington TS (1981) The biologic activity of the immunoregulatory lipoprotein, LDL-ln, is independent of its free fatty acid content. J Immunol 126: 1382–1386PubMedGoogle Scholar
  9. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey W II, Haase AT (1991) Neuropathological changes in scrapie and Alzheimer’s disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol 65: 4759–4768PubMedGoogle Scholar
  10. Epand RM (1986) Virus replication inhibitory peptides inhibit the conversion of phospholipid bilayers to the hexagonal phase. Biosci Rep 6: 647–653PubMedCrossRefGoogle Scholar
  11. Goodrum JF (1991) Cholesterol from degenerating nerve myelin becomes associated with lipoproteins containing apolipoprotein E. J Neurochem 56: 2082–2086CrossRefGoogle Scholar
  12. Hussain MM, Mahley RW, Boyles JK, Fainaru M, Brecht WJ, Lindquist PA (1989) Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits. Factors that modify tissue-specific uptake. J Biol Chem 264: 9571–9582PubMedGoogle Scholar
  13. Ignatius MJ, Shooter EM, Pitas RE, Mahley RW (1987) Lipoprotein uptake by neuronal growth cones in vitro. Science 236: 959–962PubMedCrossRefGoogle Scholar
  14. Levinson DJ (1989) Clinical gout and the pathogenesis of hyperuricemia. In: McCarthy DJ (ed) Arthritis and Allied Conditions. Lea and Fibiger, Philadelphia, p 16–91Google Scholar
  15. Mahley RW, Weisgraber KH, Hussain MM, Greenman B, Fisher T, Vogel T, Gorecki M (1989) Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest 83: 2125–2130PubMedCrossRefGoogle Scholar
  16. Owens RJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP (1990) Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immuno-deficiency virus-induced syncytium formation. J Clin Invest 86: 1142–1150PubMedCrossRefGoogle Scholar
  17. Pepe MG, Curtiss LK (1986) Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 136: 3716–3723PubMedGoogle Scholar
  18. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917: 148–161PubMedGoogle Scholar
  19. Richardson CD, Choppin PW (1983) Oligopeptides that specifically inhibit membrane fusion by paramyxoviruses: studies on the site of action. Virology 131: 518–532PubMedCrossRefGoogle Scholar
  20. Robey WG, Safai B, Oroszlan S, Arthur LO, Gonda MA, Gallo RC, Fishinger PJ (1985) Characterization of envelope and structural gene products of HTLV-III with sera from AIDS patients. Science 228: 1402–1405CrossRefGoogle Scholar
  21. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature 353: 265–267PubMedCrossRefGoogle Scholar
  22. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap M (1985) Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 39: 1–8PubMedCrossRefGoogle Scholar
  23. Skene JHP, Shooter EM (1983) Denervated sheath cells secrete a new protein after nerve injury. Proc Natl Acad Sci USA 80: 4169–4173PubMedCrossRefGoogle Scholar
  24. Snipes GJ, McGuire CB, Norden JJ, Freeman JA (1986) Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells. Proc Natl Acad Sci USA 83: 1130–1134PubMedCrossRefGoogle Scholar
  25. Srinivas RV, Birkedal B, Owens RJ, Anantharamaiah GM, Segrest JP, Compans RW (1990) Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. Virology 176: 48–57PubMedCrossRefGoogle Scholar
  26. Srinivas RV, Venkatachalapathi YV, Rui Z, Owens RJ, Gupta KB, Srinivas SK, Anantharamaiah GM, Segrest JP, Compans RW (1991) Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs. J Cell Biochem 45: 224–237PubMedCrossRefGoogle Scholar
  27. Terkeltaub RA, Dyer CA, Martin J, Curtiss LK (1991) Apolipoprotein (Apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. J Clin Invest 87: 20–26PubMedCrossRefGoogle Scholar
  28. Yamada N, Shimano H, Mokuno H, et al (1989) Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hypolipidemic rabbits. Proc Natl Acad Sci USA 86: 665–669PubMedCrossRefGoogle Scholar
  29. Yamada N, Inoue I, Kawamura M, et al. (1992) Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 89: 706–711PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Cesare R. Sirtori
    • 1
  1. 1.Center E. Grossi Paoletti, Institute of Pharmacological SciencesUniversity of MilanoMilanoItaly

Personalised recommendations